

An Overview on ICH Guidelines: New Inclusions

Sarika Joga¹, Alkeya Theerthala², Vytla Shruthi³

Assistant Professor, Department of Pharmacology¹

Students, , Department of Pharmacology^{2,3}

Sarojini Naidu Vanitha Pharmacy Maha Vidyalaya, Tarnaka, Hyderabad.

Abstract: *The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) plays a pivotal role in unifying global standards for pharmaceutical development, regulatory approval, and manufacturing. Among its extensive guidelines, the recent inclusions of ICH Q13 and Q14 mark significant advancements in the realm of continuous manufacturing and analytical procedure development. ICH Q13 addresses the increasing adoption of continuous manufacturing (CM) processes in the pharmaceutical industry. Unlike traditional batch manufacturing, CM allows for the ongoing production of pharmaceuticals, which can enhance efficiency, consistency, and scalability. This guideline provides a framework for the implementation of CM, focusing on the technical and regulatory considerations necessary for its adoption. ICH Q14 focuses on modernizing the development and validation of analytical procedures. Analytical methods are critical for ensuring the quality, safety, and efficacy of pharmaceutical products. Q14 aims to streamline the development process, enhance method robustness, and facilitate regulatory approval. The inclusion of ICH Q13 and Q14 represents a significant stride towards enhancing pharmaceutical manufacturing and analytical practices. ICH Q13 facilitates the transition to continuous manufacturing, promising greater efficiency and product consistency, while ICH Q14 modernizes analytical method development, ensuring robust and reliable procedures. Together, these guidelines reflect the ICH's commitment to fostering innovation, regulatory flexibility, and global harmonization in the pharmaceutical industry.*

Keywords: Analytical methods

